Celltrion said on the 9th that Remsima, its autoimmune disease treatment, recorded a 95% market share in Singapore in the third quarter of last year. According to IQVIA, a pharmaceutical market research firm, Remsima also had high shares in Hong Kong (77%), Thailand (73%), and Malaysia (65%). Remsima is a biosimilar of Johnson & Johnson's Remicade.
Yuflyma, an autoimmune disease treatment, ranked second in market share in Singapore. Celltrion's Singapore subsidiary plans to introduce a 20 mg dose in addition to the 40 mg Yuflyma. The company noted that in Asia, where procurement is tender-based, it increased its win rate by emphasizing supply stability.
Celltrion is also introducing oncology drugs in Asia. Herzuma, a treatment for breast and gastric cancers, recorded an 87% market share in Thailand in the third quarter of last year. Truxima's market share for hematologic cancers is 90% in Singapore and 79% in Thailand.
Celltrion plans to expand biosimilar prescriptions in Asia through a direct sales system. It aims to obtain approval within the year in Singapore for the bone disease treatment Stoboclo Osenbelt. In Thailand, it plans to introduce the autoimmune disease treatment Steqeyma, the metastatic colorectal and breast cancer treatment Vegzelma, and the allergy disease treatment OMLYCLO. A Celltrion official said, "We will achieve early market establishment and improved revenue."